Application of Houttuynoid A in anti-human fungus drugs

An antifungal and drug technology, applied in antifungal agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problems of digestive tract irritation, strong accumulation of toxicity, etc. active effect

Inactive Publication Date: 2013-01-30
NANJING UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The spread of pathogenic bacteria and the enhancement of drug resistance seriously threaten human health and life. Antibacterial drugs have been widely used as routine drugs in the treatment of AIDS, organ transplantation and chronic wasting diseases (such as cancer, diabetes, uremia, etc.) Treatment, although antibacterial agents currently used clinically (such as ketoconazole, amikacin, gentamicin, vigorconazole, itraconazole, terbinafine, amphotericin, fluconazole, etc.) The curative effect on skin and superficial infection is good, but these antibacterial drugs have strong cumulative toxicity, often causing liver and kidney damage, gastrointestinal irritation, dizziness, allergies, etc. one of the hotspots

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Houttuynoid A in anti-human fungus drugs
  • Application of Houttuynoid A in anti-human fungus drugs
  • Application of Houttuynoid A in anti-human fungus drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1: the preparation of compound Houttuynoid A tablet involved in the present invention:

[0014] Take 20 grams of compound Houttuynoid A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.

Embodiment 2

[0015] Embodiment 2: the preparation of compound Houttuynoid A capsule involved in the present invention:

[0016] Get 20 grams of compound Houttuynoid A, add conventional auxiliary materials such as starch 180 grams for preparing capsules, mix well, and pack into capsules to make 1000 tablets.

[0017] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example

[0018] Experimental example: Anti-fungal activity of Houttuynoid A in humans

[0019] Anti-human fungus activity experiment is the method of concentration dilution, each determination is repeated three times, the test pathogens include Trichomonas rubrum, Microsporum lanoides and Phytophthora clematis, and the concentration of the bacterial solution is 10 5 individual / mL. The initial concentration of Houttuynoid A is 50.0 μg / mL (5% dimethyl sulfoxide DMSO), serially diluted to 0.098 μg / mL, and the same volume of bacterial liquid and test samples are mixed and cultured in a 96-well plate, and the human fungal culture temperature 28 ℃ respectively, observe after 24 hours of incubation time, if no colony is found, it is the lowest anti-human fungal concentration of the sample, that is, the MIC value. The positive control of this experiment is ketoconazole, and the anti-human fungus results of Houttuynoid A are shown in Table 1.

[0020] Table 1 Houttuynoid A anti-human fungal M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of Houttuynoid A in preparing anti-human fungus drugs and belongs to the field of medicines. The Houttuynoid A is very powerful in effect of inhibiting trichophyton rubrum, microsporum lanosum or trichophyton tonsurans, and therefore, the Houttuynoid A can serve as an anti-human fungus compound, and is expected to be applied in preparing related drugs. The application of the Houttuynoid A in preparing the anti-human fungus drugs is disclosed for the first time. As the skeleton type of the Houttuynoid A is fire-new, and the inhibitory activity of the Houttuynoid A on human fungi is unexpectedly strong, the possibility that any enlightenments are given by other compounds does not exist. The Houttuynoid A is outstanding in substantive feature, and meanwhile, apparently makes a significant progress when being used for preventing and curing human fungus infections.

Description

technical field [0001] The invention relates to the application of Houttuynoid A, in particular to the application of Houttuynoid A in the preparation of antifungal drugs for human body. Background technique [0002] The spread of pathogenic bacteria and the enhancement of drug resistance seriously threaten human health and life. Antibacterial drugs have been widely used as routine drugs in the treatment of AIDS, organ transplantation and chronic wasting diseases (such as cancer, diabetes, uremia, etc.) Treatment, although antibacterial agents currently used clinically (such as ketoconazole, amikacin, gentamicin, vigorconazole, itraconazole, terbinafine, amphotericin, fluconazole, etc.) The curative effect on skin and superficial infection is good, but these antibacterial drugs have strong accumulation toxicity, often causing liver and kidney damage, gastrointestinal irritation, dizziness, allergies, etc. one of the hotspots. [0003] The compound Houttuynoid A involved in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P31/10
Inventor 俞骁王泽正吴俊华
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap